MDS 2023 | Treating Parkinson’s disease dementia: challenges and progress

Stephen Pasternak, MD, PhD, FRCPC, Robarts Research Institute, Western University, London, Ontario, Canada, sheds light on the limited treatment options available for patients with dementia, particularly those with Parkinson’s disease. While some drugs, like cholinesterase inhibitors, offer some relief in Alzheimer’s disease, their efficacy in Parkinson’s disease dementia is still a subject of debate. The first positive clinical trials have raised hopes for potential benefits, but more research is needed to determine their true value. Currently, aside from medication, there are no interventions to alter the course of the disease in Parkinson’s dementia. Thus, the medical community eagerly awaits the development of new drugs that can potentially modify the disease trajectory. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.